From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

CHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSINESS WIRE)--BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service ...

In the dynamic world of mRNA lipid nanoparticle (mRNA-LNP) technology, scientists are quickly moving beyond infectious disease vaccines into a range of new modalities and applications. However, the ...

In a recent study published in PNAS, researchers presented a scalable lipid nanoparticle (LNP) production (SCALAR) platform to produce high-throughput lipid nanoparticles on one microfluidic chip and ...

Product Performance – potency and dosing: Cryogenic transmission electron microscopy (Cryo-TEM) revealed more uniform, solid-core particles. Increased lipid and RNA concentrations can enhance in vivo ...

COLCHESTER, Vt.--(BUSINESS WIRE)--Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of ...

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ ...

Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, ...